Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer

Amendments: Author Correction: ClampFISH detects individual nucleic acid molecules using click chemistry–based amplification

(2019) Sara H Rouhanifard et al.   NATURE BIOTECHNOLOGY

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data

(2018) Dimitrios Zardavas et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

(2017) Jane Goodall et al.   Cancer Discovery

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes

(2017) Ji-Yeon Kim et al.   Oncotarget

PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

(2016) Charlotte Fribbens et al.   JOURNAL OF CLINICAL ONCOLOGY

ActivatingESR1Mutations Differentially Affect the Efficacy of ER Antagonists

(2016) Weiyi Toy et al.   Cancer Discovery

p53 in the DNA-Damage-Repair Process

(2016) Ashley B. Williams et al.   Cold Spring Harbor Perspectives in Medicine

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

(2016) Celine Lefebvre et al.   PLOS MEDICINE

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

(2015) Kenneth S. Thress et al.   LUNG CANCER

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

(2013) K. Merenbakh-Lamin et al.   CANCER RESEARCH

Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients

(2013) V. Taly et al.   CLINICAL CHEMISTRY

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

(2013) Stephen RD Johnston et al.   LANCET ONCOLOGY

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

(2013) Weiyi Toy et al.   NATURE GENETICS

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

(2013) Dan R Robinson et al.   NATURE GENETICS

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

(2013) Shunqiang Li et al.   Cell Reports

Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA

(2012) T. Forshew et al.   Science Translational Medicine

Field guide to next-generation DNA sequencers

(2011) TRAVIS C. GLENN   Molecular Ecology Resources

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

(2010) Ruth E. Board et al.   BREAST CANCER RESEARCH AND TREATMENT

PIK3CA Mutations in In situ and Invasive Breast Carcinomas

(2010) A. Miron et al.   CANCER RESEARCH